Lysophospholipids: effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis.
Camejo
Germán
G
AstraZeneca Cardiovascular Discovery, Mölndal S-431 83, Sweden. German.Camejo@astrazeneca.com
D001011:Aorta / Q000166:cytology; D050197:Atherosclerosis / Q000150:complications*; D002114:Calcinosis / Q000209:etiology*; D050171:Dyslipidemias / Q000150:complications; D006801:Humans; D008244:Lysophosphatidylcholines / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D008244:Lysophosphatidylcholines